Imperial College London
Portrait Picture

Dr John S Tregoning

Faculty of Medicine, Department of Infectious Disease

Professor in Vaccine Immunology
 
 
 
//

Contact

 

john.tregoning Website

 
 
//

Location

 

456 (Shattock Group)Wright Fleming WingSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Cole:2021:10.1111/cei.13564,
author = {Cole, ME and Kundu, R and Abdulla, AF and Andrews, N and Hoschler, K and Southern, J and Jackson, D and Miller, E and Zambon, M and Turner, PJ and Tregoning, JS},
doi = {10.1111/cei.13564},
journal = {Clinical and Experimental Immunology},
pages = {125--133},
title = {Pre-existing influenza specific nasal IgA or nasal viral infection does not affect live attenuated influenza vaccine immunogenicity in children.},
url = {http://dx.doi.org/10.1111/cei.13564},
volume = {204},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The United Kingdom has a national immunisation program which includes annual influenza vaccination in school-aged children, using live attenuated influenza vaccine (LAIV). LAIV is given annually, and it is unclear whether repeat administration can affect immunogenicity. Since LAIV is delivered intranasally, pre-existing local antibody might be important. In this study, we analysed banked samples from a study performed during the 2017/18 influenza season to investigate the role of pre-existing influenza-specific nasal IgA in children aged 6-14 years. Nasopharyngeal swabs were collected prior to LAIV immunisation, to measure pre-existing IgA levels and test for concurrent upper respiratory tract viral infections (URTI). Oral fluid samples were taken at baseline and 21-28 days after LAIV to measure IgG as a surrogate of immunogenicity. Antibody levels at baseline were compared with a pre-existing dataset of LAIV shedding from the same individuals, measured by RT-PCR. There was detectable nasal IgA specific to all four strains in the vaccine at baseline. However, baseline nasal IgA did not correlate with the fold change in IgG response to the vaccine. Baseline nasal IgA also did not have an impact on whether vaccine virus RNA was detectable after immunisation. There was no difference in fold change of antibody between individuals with and without an URTI at the time of immunisation. Overall, we observed no effect of pre-existing influenza specific nasal antibody levels on immunogenicity, supporting annual immunisation with LAIV in children.
AU  - Cole,ME
AU  - Kundu,R
AU  - Abdulla,AF
AU  - Andrews,N
AU  - Hoschler,K
AU  - Southern,J
AU  - Jackson,D
AU  - Miller,E
AU  - Zambon,M
AU  - Turner,PJ
AU  - Tregoning,JS
DO  - 10.1111/cei.13564
EP  - 133
PY  - 2021///
SN  - 0009-9104
SP  - 125
TI  - Pre-existing influenza specific nasal IgA or nasal viral infection does not affect live attenuated influenza vaccine immunogenicity in children.
T2  - Clinical and Experimental Immunology
UR  - http://dx.doi.org/10.1111/cei.13564
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33314126
UR  - https://onlinelibrary.wiley.com/doi/10.1111/cei.13564
UR  - http://hdl.handle.net/10044/1/85378
VL  - 204
ER  -
Download